AstraZeneca investor event outlines strategic direction and pipeline progression

7 June 2022

Yesterday after the close of trading, Anglo-Swedish pharm major AstraZeneca (LSE: AZN) hosted an investor event outlining the company's strategic direction in oncology and highlighted key eprogressimerging pipeline assets.

Commenting on this in a client note, SVB Securities analyst Dr Andrew Berens said that, in breast cancer, AstraZeneca's extensive pipeline includes Enhertu (trastuzumab deruxtecan), camizestrant (oral SERD), datopotamab deruxtecan (Dato-Dxd; TROP2 antibody drug conjugate), capivasertib (AKT inhibitor), and PARP inhibitor Lynparza (olaparib).

Most importantly, with these assets, AstraZeneca management believes that the company is positioned to address the full spectrum of breast cancer. While the strategic vision for the firm in breast cancer is a lofty goal in our view, Dr Berens believes that Enhertu's DB04 and DB03 data cement the asset in HER2-high and HER2-low patients, a significant step towards addressing the full spectrum of breast cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK